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Abstract
Background: High grade serous carcinoma (HGSC) whether ovarian, tubal or primary
peritoneal, continues to be the most lethal gynecologic malignancy in the USA.
Although combination chemotherapy and aggressive surgical resection has improved
survival in the past decade, the majority of patients still succumb to chemoresistant
disease recurrence. It has recently been reported that amplification of 5q31-5q35.3 is
associated with poor prognosis in patients with high grade serous ovarian carcinoma.
Although the amplicon contains over 50 genes, it is notable for the presence of several
members of the fibroblast growth factor signaling axis. In particular, acidic fibroblast
growth factor 1 (FGF1) has been demonstrated to be one of the driving genes in
mediating the observed prognostic effect of the amplicon in ovarian cancer patients
This study seeks to further validate the prognostic value of fibroblast growth receptor 4
(FGFR4), another candidate gene of the FGF/FGFR axis located in the same
amplicon. The emphasis will be delineating the role of the FGF1/FGFR4 signaling axis
in high grade serous ovarian carcinoma, and test the feasibility of targeting the
FGF1/FGFR4 axis therapeutically.
Materials and Methods: Spearman and Pearson correlation studies on data generated
from array CGH and transcriptome profiling analyses on 51 microdissected tumor
v

samples were used to identify genes located on chromosome 5q31-35.3 that showed
significant correlation between DNA and mRNA copy numbers. Significant correlation
between FGF1 and FGFR4 DNA copy numbers was further validated by quantitative
PCR

analysis

on

DNA

isolated

from

51

microdissected

tumor

samples.

Immunolocalization and quantification of FGFR4 expression were performed on
paraffin embedded tissue samples from 183 cases of high-grade serous ovarian
carcinoma. The expression was then correlated with clinical data to assess impact on
survival. The in vitro expression of FGF1 and FGFR4 was quantified by real-time PCR
and western blot of six high-grade serous ovarian carcinoma cell lines and compared
to human ovarian surface epithelial cells to identify overexpression. The effect of FGF1
on these cell lines after serum starvation was quantified for in vitro cellular
proliferation, migration/invasion, chemoresistance and survival utilizing a combination
of commercially available colorimetric, fluorometric and electrical impedance assays.
To assess FGF1:FGFR4 specific signaling effects, FGFR4 expression was then
transiently silenced via siRNA transfection and the effects cellular proliferation and
migration in response to FGF1 were quantified. To identify relevant cellular pathways
involved, responsive cell lines were transduced with different transcription

response elements using the Cignal Lenti reporter system and treated with
FGF1 with and without transient FGFR4 knockdown. This was followed by
western blot confirmation for the relevant phosphoproteins. Anti-FGF1
antibodies and FGFR trap proteins were used to inhibit FGF1 mediated
phenotypic changes and relevant signaling in vitro. To model this effect in vivo,
orthotopic intraperitoneal tumors were established in nude mice using serous

vi

ovarian cancer cell lines that have been previously transfected with luciferase
expressing constructs. The mice were then treated with FGFR trap protein. Tumor
progression was then followed via bioluminescent imaging. To exclude presence of
activating mutations, the FGFR4 gene from 43 patients was sequenced.
Results: FGFR4 DNA and mRNA copy numbers were significantly correlated and
FGFR4 DNA copy number was significantly correlated with that of FGF1. Survival of
patients with high FGFR4 expressing tumors was significantly shorter than those with
low expression (median survival 28 vs. 55 month, p< 0.001). In a multivariate Cox
regression model, FGFR4 expression significantly increased risk of death (H.R. 2.1,
p<0.001). FGFR4 expression was significantly higher in all cell lines tested compared
to HOSE; the OVCA432 cell line, in particular, had very high expression suggesting
amplification. FGF1 was also particularly overexpressed in OVCA432. FGF1
significantly increased cell survival after serum deprivation in all cell lines. Transient
knockdown of FGFR4 caused significant reduction in cell migration and proliferation in
vitro and significantly decreased the proliferative effects of FGF1 in vitro. FGFR1,
FGFR4 traps and anti-FGF1 antibodies did not show activity in vitro. OVCA432
transfected with the Cignal Lenti reporter system revealed significant activation of
MAPK, NFkB and WNT pathways; western blotting confirmed these results. Reverse
phase protein array (RPPA) analysis also showed activation of MAPK, AKT, WNT
pathways and down-regulation of E-Cadherin. FGFR1 trap protein significantly
reduced tumor growth in vivo in an orthotopic mouse model.
Conclusions: Overexpression and amplification of several members of the FGF/FGFR
signaling axis present on the amplicon 5q31-35.3 is a negative prognostic indicator in
vii

high grade serous ovarian carcinoma and may drive poor survival associated with that
amplicon. Activation of the FGF signaling pathway leads to downstream activation of
MAPK, AKT, WNT and NFkB pathways leading to a more aggressive cancer
phenotype with increased tumor growth, evasion of serum-starved apoptosis, and
increased migration and invasion. Inhibition of the FGF pathway in vivo via FGFR trap
protein leads to significantly decreased tumor growth in an orthotopic mouse model.
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Introduction
High grade serous carcinoma (HGSC) is the most common malignant carcinoma
arising from the ovary and fallopian tube, and second most common gynecologic
cancer after corpus carcinoma in the USA [1]. It also remains the most fatal
gynecologic malignancy as most patients succumb to recurrence after successful
primary treatment with combined debulking surgery and chemotherapy [2].
Ovarian cancers are thought to arise from the tissues making up the female gonads.
Ovarian neoplasia is broadly subdivided into epithelial tumors originating from the
cuboidal epithelial cell covering the surface of the ovary, sex-cord stromal tumors
originating from connective tissue elements, and germ-line tumors originating from
remnant embryonic tissue. Epithelial tumors are by far the most common, accounting
for more than 90% of cases.
Epithelial ovarian cancers are also subdivided into several histological subtypes as
they resemble other endodermal tissues rather than the postulated tissue of origin.
Mucinous tumors resemble appendiceal tumors; they predominantly produce mucin
with abundant goblet-like cells dominating their architecture. Endometrioid tumors
resemble endometrial carcinomas with endometrial gland-like architecture. Clear cell
tumors are characterized by perinuclear clearing and production of glycogen.
Transitional cell tumors are rare and resemble urothelial epithelium (table I1).
Serous tumors are the most common type of epithelial ovarian tumors. They
histologically resemble the ciliated epithelium of the fallopian tube. Serous tumors
arising from the fallopian tube itself and the mesothelial covering of the female
peritoneum are histologically indistinguishable from serous ovarian tumors. Recently,
1

the origin of serous ovarian tumors has been challenged. Discovery of fallopian
intraepithelial neoplasia and evidence from profiling studies now point towards
fallopian tube epithelium as the tissue of origin [3].
In addition to histological subtypes, epithelial ovarian tumors are further divided into
borderline tumors, low grade, and high grade carcinomas. Borderline tumors are
characterized by lack of invasion, well-differentiated histology, and relatively indolent
course. Low grade tumors histologically resemble borderline tumors but are invasive
and are associated with a poorer prognosis. High grade tumors are the most common
subtype. They are the least differentiated of the subtypes and clinically most
aggressive. HGSCs are the most common of all high grade ovarian tumors accounting
for 60-80% of the cases [4].
Genome profiling of epithelial tumors suggests two distinct pathways for their
pathogenesis (Figure I2). Borderline tumors and low grade tumors both share a high
incidence of KRAS and BRAF mutations, and lack p53 mutations. High grade tumors,
on the other hand, are characterized by p53 mutations and lack of KRAS and BRAF
aberrations. It has been suggested that borderline and low grade tumors present a
continuum of neoplastic development that starts with activating mutations in the MAPK
pathway within ovarian inclusion cysts as the precursor lesions. High grade serous
tumors on the other hand are thought to derive from fallopian intraepithelial neoplasia
characterized by p53 loss of function [3].
The cornerstone of treatment of HGSC is primary surgical cytoreductive surgery with
the aim of reducing tumor burden to microscopic disease [5]. This is usually followed
by adjuvant combined treatment with a platinum and taxane containing chemotherapy,
2

Epithelial Ovarian Tumor Type

Representative section

Serous
(resembles Fallopian tube)

Mucinous
(resembles GI goblet glands)

Endometrioid
(resembles endometrial glands)

Clear cell
(resembles GI endoderm)

Transitional
(resembles bladder urothelium)

Table I1 .The histologic sub types of epithelial ovarian carcinomas.

3

which affords 80% of patients an initial complete response and a disease free period
ranging between twelve and twenty four months [6]. Most patients present in late stage
advance disease (stage III-IV). Abdominal and pelvic recurrence rates are high and
response to further chemotherapy is limited [7].

Attempts at introducing biologic

therapeutic agents to improve outcome in this disease are ongoing [8]; however thus
far, only the anti-VEGF antibody, bevacizumab, has been reported to have clinical
activity in a phase III clinical trials [9].
Our group has recently reported that the amplicon 5q31-35.3 is a negative prognostic
indicator in HGSC and that overexpression of fibroblast growth factor 1 (FGF1) is
implicated in reducing survival [10]. It was notable that several members of the
fibroblast growth factor family are also present on 5q31-35.3, including fibroblast
growth factor 18 (FGF18), and the fibroblast growth factor receptor 4 (FGFR4) [11],
which may also be involved in ovarian cancer progression.
Fibroblast growth factors (FGFs) are a family of small signaling proteins with a wide
range of biologic effects. To date, 18 members of the FGF family have been described
in mammals. All share a core 120 amino acid region and differ in structure at their
carboxy & amino terminals [12]. Receptor tyrosine kinases (RTKs) are the main target
by which FGF ligands induce signal transduction, although some direct nuclear
signaling has been reported [13]. FGFs are expressed in a variety of tissues and have
been implicated in angiogenesis [14], embryonic development/differentiation [15] and
tumorigenesis [16]. FGFs have been shown to signal through autocrine, endocrine and
paracrine pathways [17].

FGFs involvement in cancer biology have been well

documented [18], with different members playing diverse roles related to the cancer
4

phenotype including tumor proliferation [19], survival [20], migration/invasion [21], EMT
[22] and angiogenesis [23].

Stage Description
I

Confined to ovaries

II

Incidence

Survival

20%

90%

Confined to pelvis

5%

65%

III

Spread IP or nodes

58%

45%

IV

Distant metastases

17%

<5%

Figure I1. Distribution of stage and prognosis in ovarian epithelial carcinoma.

Figure I2. Illustration of the different pathways potentially leading to low versus high grade ovarian
carcinoma. Abbreviations: APST, atypical proliferative serous tumor; CIN, chromosomal instability; LOH, loss of
heterozygosity; MPSC, micropapillary serous carcinoma. Figure modified from reference [24] with permission.
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FGF signaling is mediated through 4 transmembrane RTKs that are a product of 4
highly conserved genes, FGFR1 through FGFR4 [12] . Through alternative splicing, 14
variants of FGFRs have been described across the 4 FGFR classes, with only FGFR4
lacking multiple isoforms [25]. The prototypical structure of FGFR consists of 3
extracellular immunoglobulin-like domains (IgI-IgIII) which impart ligand specificity at
the amino terminus, followed by a transmembrane domain and a highly conserved
split tyrosine kinase domain at the carboxy end [26].
As with many RTKs, activation of the FGF signaling axis requires FGF ligand binding
to and subsequent dimerization and autophosphorylation of FGFR [27]. This
interaction requires presence of heparin sulfate glycosaminoglycans which acts to
increase binding affinity, stabilize the ligand/ receptor dimer, and increase half life [28].
Once binding of the FGF-heparin complex occurs, receptors dimerize with subsequent
autophosphorylation of the intracellular domain tyrosine residues, paving the way for
activation of several intracellular signaling pathways [29].
FGFR downstream signaling leads to activation of several second messenger
pathways with a variety of outcomes depending on ligand, receptor, cell and tissue
type, and cross talk with other pathways [27]. The docking protein, FGFR substrate 2
(FRS2), plays a critical role in activation of MAPK/ERK and PI3K/AKT pathways
downstream of FGFR. FRS2 is bound to the juxtamembrane portion of FGFR; once
FGFR is activated and autophosphorylated, FRS2 is recruited and also undergoes
phosphorylation by the activated receptor. The phosphorylated FRS2 recruits the
adaptor proteins Sons of Sevenless (SOS) and growth factor receptor-bound 2
(GRB2), which subsequently activates RAS, downstream RAF, and eventually
6

MAPK/ERK pathway [26, 30]. Through GRB2 associated protein 1, the FGFR-FRS2GRB2 complex can also bind and activate PI3K with downstream activation of Akt [31].
The phosphorylated carboxy-terminus of FGFR can also bind the SH2 domain of
phospholipase C with subsequent activation of PKC pathway [32]. STAT pathway
activation has been described with FGFR3 but the mechanism remains unclear [33].
Termination of FGFR signaling involves feedback inhibition by several pathways. Nonspecific attenuation of FGFR signaling is mediated through RTK inhibitor pathways.
These include members of the Sprouty (Spry) family, which work by inhibition of ERK
activation through sequestration of GRB2 [34]. MKP3 (MAPK phosphatase 3) is
another inhibitor of RTK signaling that also acts by dephosphorylating ERK [35]. A
single pass transmembrane protein encoded by the SEF gene has been identified as
specific inhibitor of FGFR1, it is thought to prevent tyrosine kinase activation by biding
to the receptor, but the exact mechanism is unknown [36, 37].
Germ line mutation in the FGF pathway is involved in several skeletal dysplasias.
Activating mutations on the FGFR genes are reported in craniosynostosis (of
premature fusion of 1 or more cranial sutures) and thanatophoric dysplasia (extremely
short limbs and folds of extra skin on the arms and legs) [38]. No predisposition or
familial cancer syndromes have been reported with the FGF pathway. However, driver
mutilations with downstream activation of the pathway are known to be driver mutation
in certain types of multiple myeloma where fusion proteins produce continuous
activation of the FGFR kinase domain [39]. Aberrations in the expression and
mutations of FGFs and FGFRs in the solid tumors, to which HGSC belongs, have
been reported to play an important role in their pathogenesis (Table l1).
7

Figure I3.Structure of the 4 FGFR receptors and their different splice variants, adapted with permission from
reference [25]

Figure I4. FGF and Heparin glycosaminoglycan complex(HLGAG) bound to FGFR causing receptor dimerization
and autophosphorylation of the intracellular domain, adapted with permission from reference [25].

8

Figure I5. Downstream second messenger pathways activated by FGF signaling and associated molecules,
adapted from reference with permission [40].

Activating mutations in the kinase and intermembrane domains are reported in
approximately 50% of non-invasive bladder carcinomas [41]. Mutations of FGFR2,
which are identical to the activating germline mutations found in craniosynostosis
syndromes, have been described in 12% of endometrial carcinomas [42]. In breast
carcinomas, the 8p11-p12 amplicon, which contains FGFR1, is observed in about 10–
15% breast cancer patients [43]. Amplification and overexpression of FGFR2 is

9

observed in about 4–12% breast tumors whilst FGFR4 protein is overexpressed in
around 30% patients [44, 45].
Gene

Cancer type

References

Amplification

Breast cancer , ovarian cancer , bladder cancer and rhabdomyosarcoma

[46-50]

Mutation

Melanoma

[51]

Amplification

Gastric cancer and breast cancer

[52, 53]

Mutation

Endometrial cancer and gastric cancer

[54, 55]

Germline SNP

Second intron SNP: increased incidence of breast cancer

[56, 57]

Amplification

Bladder , salivary adenoid cystic cancers

[58, 59]

Mutation

Bladder cancer , cervical cancer , prostate and spermatocytic seminoma

[41, 60-64]

Mutation

Rhabdomyosarcoma

[65]

Germline SNP

Coding SNP: poor prognosis breast, colon and lung adenocarcinoma

[66, 67]

Ovarian

[10]

FGFR1

FGFR2

FGFR3

FGFR4

FGF1
Amplification

Table I2. FGF/FGFR axis aberrations reported for various solid tumors.

Activating mutations in the kinase and intermembrane domains are reported in
approximately 50% of non-invasive bladder carcinomas [41]. Mutations of FGFR2,
which are identical to the activating germline mutations found in craniosynostosis
syndromes, have been described in 12% of endometrial carcinomas [42]. In breast
carcinomas, the 8p11-p12 amplicon, which contains FGFR1, is observed in about 10–
15% breast cancer patients [43]. Amplification and overexpression of FGFR2 is
10

observed in about 4–12% breast tumors whilst FGFR4 protein is overexpressed in
around 30% patients [44, 45]. FGFR2 amplification has been found in up to 10% of
primary gastric cancers[55], activating mutations have also been found in FGFR2 in
primary gastric cancers [68]. The SNP Gly388Arg has been reported to be a poor
prognostic indicator in breast, lung, and colon carcinomas [67].
Since FGFR inhibition can reduce proliferation and induce cell death in a variety of in
vitro and in vivo tumor models, inhibitors of FGFR or FGFR-dependent downstream
signaling pathways may represent useful therapeutic agents. FGFR inhibition can be
achieved by several approaches and both small molecule tyrosine kinase inhibitors
directed against FGFR activity, and FGFR-antagonistic antibodies and trap protein
have been described[40].
In undertaking this investigation, we aim to build on evidence that the amplification of
FGF pathway related genes on segment 5q31-35.3 negatively impacts survival in
HGSC, and to explore possible avenues to intervene therapeutically to improve
outcome in those patients.

11

Hypothesis and Specific Aims
We hypothesize that fibroblast growth factor pathway activation is one of the main
factors in conferring poor prognosis associated with amplification of 5q31-35.3 in highgrade serous carcinoma. The amplification and overexpression of FGF1 ligand by
such tumors stimulate ovarian cancer growth and survival 1) directly through autocrine
signaling via several second messenger pathways or 2) indirectly through stimulating
angiogenesis in a paracrine manner as previously reported. In addition, we
hypothesize that FGFR4 is another driving gene located in the same amplicon where
FGF1 is located. Binding of FGFR4 ligands, including FGF1 activates the downstream
signaling pathways, which promote ovarian cancer growth and lead to poorer patient
survival. The hypothesized overexpression of FGF ligands and the FGFR4 receptor in
HGSC suggest that use of biologic agents targeted to that pathway may be of
therapeutic benefit.

Figure H1. Illustration of central hypothesis.

12

The specific aims are as follows:
1. To quantify the expression of FGFR4 in HGSC, correlate its expression to that of
FGF1, and determine its impact on survival.
2. To identify the mechanisms by which FGF1/FGFR4 overexpression and activation
impact HGSC cell behavior.
3. To identify signaling pathways in HGSC related to the FGF1/FGFR4 axis.
4. To target the FGF1/FGFR4 axis in HGSC with suitable biologic agents to
determine feasibility of therapeutic intervention.
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Methods
Validation of FGFR4/FGF1 amplification in tumor samples
Based on previously reported CGH data [10], validation of gene copy number on
segment 5q31-35.3 was done by quantitative polymerase chain reaction (qRT-PCR) to
assess relative copy number of the genes of interest. Sixty-three DNA samples were
extracted as previously described for CGH analysis [10], and amplified by GenomiPhi
whole genome amplification system (Amersham, Piscataway, NJ) according to the
manufacturer’s instructions. qRT-PCR was then performed using primers specific for
each gene using SYBR green as per manufacturer’s instructions (Qiagen Sciences
Inc, Germantown, MD). DNA content was normalized to that of Line-1, a repetitive
element for which copy numbers per haploid genome are similar among all normal and
neoplastic cells. Relative DNA copy number was determined by normalizing to that of
normal human ovarian surface epithelial cells. Correlations between DNA copy
number fold change and survival data were performed using Cox regression and
Kaplan-Meier analysis.

Patient samples
Paraffin sections from 183 late stage high grade serous ovarian carcinoma cases were
obtained from the pathology repository at the University of Texas M.D. Anderson
Cancer Center under the approval of the Institution Review Board (IRB). Clinical/
pathologic data regarding age, stage, histology, overall survival, and extent of residual
disease after surgery was available for these sections.

14

Immunolocalization of FGFR4
Tumor sections underwent deparaffinization by incubation in xylene for 5 minutes and
then rehydration in decreasing concentrations of alcohol in water. Antigen retrieval
was then performed by heating slides to 95oC for 10 minutes in citric acid buffer (pH
6.0). The sections then underwent immunohistochemistry staining utilizing the
Labvision 360 Automated Stainer (Labvision Corp, Fremont, CA). A commercially
available FGFR4 antibody was used to specifically bind FGFR4 in the fixed tissue (sc124 Santacruz biotech, Santa Cruz, CA). Parameters for the IHC cycle were as
follows:
Step

Reagent (lab vision Corp, Fremont CA)

Incubation time

Endogenous peroxidase block

Hydrogen peroxide block solution

15 minutes

Protein background block

Ultra V block solution

5 minutes

Primary antibody incubation

SC-124 , 1:50 dilution

90 minutes

Secondary conjugated polymer

Ultravision LP HRP polymer

15 minutes

Chromogen application and development

DAB Plus substrate

5 minute

Hematoxylin counter stain

Mayer Hematoxylin solution

1 minute

Digital photomicrographs of representative areas were taken at 20x magnification.
Quantitative FGFR4 stain intensity and localization measurements were obtained by
using ImagePro Plus software version 5.1, Figure 1M (Media Cybernetics Inc.,
Bethesda MD).

15

The resulting FGFR4 stain intensity score was used to divide the patients into low and
high FGFR4 expression groups using the median as a cutoff point. Survival analysis
utilizing both the Kaplan-Meier modeling (with log-rank significance testing) and Cox
proportional hazard model were performed to determine effect on overall survival and
risk of death.

Figure M1. Computer assisted quantification of FGFR4 staining intensity in high-grade ovarian serous carcinoma.
Representative images of FGFR4 IHC signal with corresponding measurement and heat map generated by software algorithm
in (A) patient with overall survival of 10 months and (B) patient with overall survival of 90 months.
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Cell lines and culture conditions
The derivation and source of the human epithelial ovarian cancer cell lines A2780,
SKOV3ip,OVCAR-3,OV5,OVCA432 ,OVCA433 have been described previously [6973].

All cell lines were maintained and propagated in RPMI-1640 medium

supplemented with 10% fetal bovine serum (FBS) and 0.1% gentamicin sulfate
(Mediatech Inc., Manassas, VA).
Generation of OVCA432 luciferase reporter cell lines was performed by transducing
the parental cell line with lentiviral particles containing expression plasmids encoding
for transcription response elements for MAPK, PI3K, WNT, NFKB, NOTCH, JAK/STAT
pathways linked to a luciferase expression system (Cignal Lenti, SA Bioscience Corp,
Frederick, MD) according to the manufacturer’s instructions.
Generation of the luciferase expressing cell line 432luc was done via transduction with
lentiviral particles containing a luciferase expression system under a CMV promoter
(Genetarget, Inc, San Diego, CA) according to the manufacturer’s instructions.
All experiments were performed using cells grown to 60-80% confluence. All cell lines
were routinely genotyped and tested to confirm absence of mycoplasma. Passage
number for cell lines did not exceed 20.
Quantification of FGFR4 & FGF1 expression in vitro
A) Protein quantification
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To quantify FGF1/FGFR4 protein expression in vitro for wild type cells lines and those
after treatment or knockdown, lysates were prepared from cells in log phase growth at
70-80% confluence. Cells were washed with PBS, harvested by scraping, and lysed
with modified radioimmunoprecipitation assay (RIPA) lysis buffer (20 mM Tris-HCl (pH
7.5), 150 mM NaCl, 1 mM Na2EDTA, 1 mM EGTA, 1% NP-40, 1% sodium
deoxycholate, 2.5 mM sodium pyrophosphate, 1 mM b-glycerophosphate, 1 mM
Na3VO4, 1 µg/ml leupeptin) supplemented with 1x protease/phosphatase inhibitor
cocktail (Thermofisher Scientific, Waltham, MA). Cell lysate was centrifuged at 13,400
rpm for 10 min at 4ºC. Protein concentration was determined by a Pierce 660 nm
Protein

Assay kit

(Thermofisher

Scientific,

Waltham,

MA)

according

to

the

manufacturer’s instructions. A total of 30 µg of protein from whole-cell lysate was
subjected to SDS-PAGE on a 10% gel for 2 h at a constant 90 volts, then transferred
to a nitrocellulose membrane utilizing semi-dry transfer method (Bio-Rad Labs,
Hercules, CA). The membrane was then blocked with 3% bovine serum albumin
solution for 1 hr at room temperature and probed with commercially available primary
antibodies (Anti-FGFR4:MAB6852, dilution 1:500, Anti-FGF1:AF232, dilution 1:1000,
both from R&D Biosystems, Minneapolis, MN, and Anti-beta-actin, A1978, dilution
1:10,000, Sigma Aldrich, St Louis, MO) at 4ºC overnight. The membranes were rinsed
three times for 10 minutes each in tris-buffered saline (concentration of TBS?) with
0.1% Tween twenty. Incubation for the secondary antibody was done for one hour at
room temperature. The secondary antibodies used were IR-680LT goat anti-mouse,
IR-800CW donkey anti-goat and IR-800CW goat anti-rat (Li-Cor Biotechnology,
Lincoln, NE). A 1:5000 dilution was used for all secondary antibodies. The membrane
was rinsed 3 times for 10 minutes each to reduce background signal. The membranes
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underwent infrared imaging on a Li-Cor Odyssey system (Li-Cor Biotechnology,
Lincoln, NE). Results were visualized using packaged software, which also performed
quantitative band analysis via normalization to beta-actin.

B) Messenger RNA quantification
To quantify mRNA expression of genes under investigation, cells were grown to a
density of 1x105 cells in six well plates; the media was then removed and washed with
PBS at 4°C. RNA was then isolated by lysing and processing the cells via the Ambion
Purelink RNA minikit (Invitrogen Corporation, Carlsbad, CA). Quality of collected RNA
was then verified using a Nanodrop ND-1000 spectrophotometer (Thermofisher
Scientific, Waltham, MA)-. cDNA synthesis was performed with the high capacity
cDNA reverse transcription kit (Applied Biosystems, Carlsbad, CA). Quantitative RTPCR (qRT-PCR): Quantitative RT-PCR was performed by TaqMan approach using
the CFX96 Quantitative Real-Time PCR system (Bio-Rad Labs, Hercules, CA).
FGFR4 expression levels were determined by TaqMan assay (Hs00242558-m1) while
a Cyclophilin TaqMan probe (4326316E) was used as an endogenous control.
TaqMan assays were performed according to the manufacturer’s suggested protocol
utilizing a universal PCR master mix (Applied Biosystems, Carlsbad, CA). Packaged
software from the CFX96 system was used to analyze the data.

C) Quantification of FGF1 in conditioned medium
To assess the level of FGF1 production by HGSC in vitro, cells were grown to 80%
confluence at which point the medium was changed to serum free Opti-MEM
(Invitrogen Corporation, Carlsbad, CA) and incubated for 48 h. The media was
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subsequently collected and concentrated by filter centrifugation, after which ELISA for
FGF1 was performed via quantakine FGF1 kit (R&D Biosystems, Minneapolis, MN).

FGFR4 gene silencing via siRNA Transfection
Two commercially available validated siRNAs targeted at FGFR4 and a non-target
scramble sequence siRNA as a control were used to perform transient knockdown of
the receptor in the cell lines under investigation (Qiagen Sciences Inc, Germantown,
MD). Information regarding these siRNAs is given in table M1. Screening for
successful knockdown was performed at the protein level and mRNA level for the cell
lines in question utilizing western blot and qRT-PCR protocol described earlier (figure
M2 & M3). Transfection was carried out according to the recommended cell densities
and transfection reagent concentrations as suggested for reverse transcription with the
Lipofectamine RNAi MAX (Invitrogen Corporation, Carlsbad, CA) transfection reagent.
The concentration of siRNA used was 10nM final concentration for all siRNA duplexes
and experiments.
siRNA ID
(target gene)

Target sequence

AllStars Neg. Control siRNA
(No target scramble
sequence)

CAGGGTATCGACGATTACAAA

Hs_FGFR4_5
(FGFR4)

CCGCCTGACCTTCGGACCCTA

Hs_FGFR4_6
(FGFR4)

CAGGCTCTTCCGGCMGTCM

Sequence
Sense
GGGUAUCGACGAUUACAAAUU
Anti sense
UUUGUAAUCGUCGAUACCCUG
Sense
GCCUGACCUUCGGACCCUATT
Anti sense
UAGGGUCCGAAGGUCAGGCGG
Sense
GGCUCUUCCGGCAAGUCAATT
Anti Sense
UUGACUUGCCGGAAGAGCCTG

Table M1. siRNA oligonucleotides used in transfection experiments targeting transient knock down of FGFR4 in
HGSC cell lines.
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Assessment of cellular proliferation/migration
A). Endpoint assays
Proliferation was assessed utilizing the WST-1 colorimetric assay (Roche Applied
Bioscience, Indianapolis, IN). Cell were plated at a density of 5,000 cells per 96 well
and allowed to attach for 24 h in serum free Opti-MEM. If siRNA transfection
No siRNA

Hs_FGFR4_5

Hs_FGFR4_6

Non target siRNA

FGFR4

actin

Figure M2. Knock down of FGFR4 in OVCA432 after 72 h of transfection at 10 nm final concentration with different
oligonucleotides.
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Figure M3. Knock down of FGFR4 in HGSC at the mRNA level as measured by real time quantitative PCR after 72
h of transfection at a final concentration of 10 nm.
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was needed, a reverse transfection was carried at this time. After the 24 h period,
media was then changed with media containing 2% FBS and any planned
recombinant FGF1 treatment (R&D Biosystems, Minneapolis, MN). The cells were
incubated for 3 days after which media was removed and WST-1 reagent diluted in
serum free media according to the manufacturer’s instruction was added and
incubated for 2 h. The assay was then quantified by a spectrophotometric plate reader.
All data were normalized to respective control arms.
Migration of HGSC cell lines was assessed with the ORIS migration assay kit
(Platypus Technologies, Madison, WI). Cells were plated at density of 30,000 per well
in serum free Opti-MEM into the 96 well plates provided with the assay, with the
stoppers in place covering the central migration zone according to manufacturer’s
instruction. If a siRNA transfection was needed, a reverse transfection was carried at
this time. Cells were left to attach for 24 h after which media containing 2% FBS and
any planned recombinant FGF1 treatment was added. The stoppers were left in for a
further 12 h and then removed to allow cell migration into the central zone for 12 h.
Cells were then stained with Calcien AM (Invitrogen Corporation, Carlsbad, CA)
according to manufacturer’s instructions. Migration was assessed by measuring
fluorescence in the central migration zone by a plate reader according to the protocol
provided with the ORIS assay. Photomicrographs were also taken with a fluorescent
microscope.
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B. Real time assays
To assess cell proliferation and migration in real-time, the xCELLigence system
(Roche Applied Bioscience, Indianapolis, IN) was used. The system measures
electrical impedance across micro-electrodes integrated on the bottom of tissue
culture plates. Impedance measurement provides quantitative information about the
biological status of the cells, including cell number [74], and migration [75, 76]. Cells
were plated at a density of 10,000/well cells for cell proliferation plates and 30,000/well
for cell migration chambers in serum free Opti-MEM. For cell proliferation, cells were
allowed to attach for 6-12 h and normalized to that point after which recombinant
FGF1 was added and cell proliferation was followed on attached computer terminal
and software. For migration studies, media in the upper chamber was devoid of FGF1
while media in the lower chamber contained FGF1 at various concentrations.

Figure M4. Real time measurement of effect of siRNA FGFR4 knock down. siRNA and transfection reagent
were mixed with cells prior to plating in wells with an electrode matrix at the bottom. The system allows realtime
data acquisition of cell number as measured through changes in electric impendence across the well bottom.
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siRNA

Figure M5. Use of wound healing assay to assess effects of FGFR4 knock down on migration of HGSC. The
system utilizes a stopper to create a central acellular zone into which the cells can migrate into after it has been
removed. The system allows siRNA transfection to be done at the same time as cell seeding and also allows
quantitative migration assessment.

Assessment of cellular signaling induced by FGF1
Cignal Lenti luciferase assay
OVCA432 cell line transected with different reporter response elements from the
Cignal Lenti reporter system were plated at a density of 30000 cells/well in 96 well
plates (in serum free media) and allowed to attach to for 24 h. The media was then
removed. Media containing 10 ng/ml FGF1 was added and allowed to incubate for 6
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hours. The media was then removed and the cells were washed with PBS once. An
assay specific cell lysis buffer was then used to lyse the cell according to the
manufacturer’s instructions (Promega Corporation Madison, WI). The plates were then
processed by a plate reader with luminescence measurement capability, and a built-in
injector. The injector dispensed 50 ul of luciferin solution per well and the
luminescence was measured as recommended by the manufacturers protocol
(Promega corporation Madison, WI). Data were normalized to their respective control
groups.

Reporter Cell Line

Luciferase Assay
Reporter gene
(Firefly luciferase)

Transcription response element
(Promoter sequence for specific biochemical pathway)

FGF1

Transcription
factor

Luciferase
Luciferin
substrate

Luminescence
measurement

Figure M6. Use Reporter assay to screen for FGF1 pathway activation in HGSC. To screen pathway activation
downstream of FGF pathway we constructed reporter cell lines in OVCA432 carrying response elements linked
luciferase. Once treated with FGF 1 if the pathway is activated induced expression of luciferase will begin, in the
presence of luciferin luminescence will be observed which we can measure as an indicator of pathway activation

Reverse phase protein array
OVCA432 were grown in six well plates until 80% confluent. Cells were then serum
starved for 24 h. FGF1 at 10 ng/ml was then added to the experimental wells and
incubated for 3 h. The cells were processed and the lysates were subjected to RPPA
at the MD Anderson Core proteomics laboratory using their previously reported
protocol [77, 78]

25

Western blotting
To confirm results of the reporter assay and RPPA, western blots of lysates from
FGF1 treated cells versus serum starved controls were performed according to the
protocol described earlier for FGFR4 with the substitution of different primary
antibodies against the proteins of interest. These antibodies are given in the table
below.
Antibody

Dilution

Manufactures

Total Erk(L34F12)

1:1000

Cell Signaling(Beverly, MA )

Phospho Erk(D13.14.4E)

1:1000

Cell Signaling(Beverly, MA )

Total Akt(40D4)

1:1000

Cell Signaling(Beverly, MA )

Phospho Akt(D9E)

1:1000

Cell Signaling(Beverly, MA )

NFKB p65 (93h1)

1:1000

Cell Signaling(Beverly, MA )

Phospho NFKB p65(C22B4)

1:1000

Cell Signaling(Beverly, MA )

Sequencing of FGFR4
DNA from 43 microdissected clinical samples was isolated and amplified as described
earlier for CGH. PCR amplification of FGFR4 exons 9-16 (intermembrane and kinase
domain) followed by purification and sequencing was performed as previously
published [65]. The primer sequences used are given in table M2.
Therapeutic targeting of FGF pathway in vitro
An OVCA432-luciferase-transfected cell line (OVCA432-Luc) was generated in our
laboratory as described earlier. An FGFR1 Fusion trap protein currently under
development as a biologic therapeutic, FP-1039, was obtained from Fiveprime
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Therapeutics Inc, San Francisco, CA (Figure M7).

On day 1, the mice received

intraperitoneal (IP) injections of 1x106 OVCA432-Luc cells and were subsequently
divided into 2 groups of 10 each. The experimental group received 20 mg/Kg FP1039
IP twice weekly while the control group received pooled human IgG at the same dose
and schedule (Sigma Aldrich Corp, St Louis MO). Bioluminescence imaging was used

Figure M7. Structure and binding ability of FP-1039 .FP-1039 is a soluble fusion protein consisting of the
extracellular domains of human FGFR1 linked to the Fc region of human Immunoglobulin G1 (IgG1) FP-1039 is
designed to bind multiple FGF ligands and prevent them from activating multiple FGF receptors.

to follow tumor development in the mice on a biweekly basis. Imaging was performed
on a the IVIS 100 imaging system with a data acquisition computer running Living
Image software (Caliper Life Science , Hopkinton, MA). Before imaging, animals were
anesthetized with a 1.5% isoflurane/air mixture and followed by injecting IP. with 15
mg/mL of D-luciferin firefly potassium salt (Caliper Life Sciences, Hopkinton, MA) in
PBS at a dose of 150 mg/kg body weight. A digital gray-scale animal image was
acquired followed by acquisition and overlay of a pseudocolor image representing the
27

spatial distribution of detected photon emerging from active luciferase within the
animal. The animals were followed for a total of 8 wks after which the animals were
sacrificed. Tumors were recovered, weighed, and processed for histological
evaluation.

Exon 9 -10
Forward

5'-GCTGGGAGGGACTGAGTTAG-3’

Reverse

5’-TGGAGAAAGTCCAGCCTCAG-3’

Exon 11
Forward

5'- CTACCTCTCGACCCACTATG-3’

Reverse

5’- GTCTTGCCATGTTGCCCAGG -3’

Exon 12
Forward

5'- GATTCAGCCCTAGACCTACG-3’

Reverse

5’- CACTCCACGATCACGTAC -3’

Exon 13
Forward

5'- CAACCTGCTTGGTGTCTG -3’

Reverse

5’- GGAAAGCGTGAATGCCTG -3’

Exon 14
Forward

5'- TGGTGTGTGCTCAACTCCAG-3’

Reverse

5’- GTACACCCGGTCAAACAAGG -3’

Exon 15
Forward

5'- CCAGCAACGTGAGGGAGATG-3’

Reverse

5’- CCAAATCTGAAGGAGCCCTCG -3’

Exon 16
Forward

5’-TGTCCTACCCCACAAAAAGG-3’

Reverse

5’-AGGAGGACGAGGAGTTGTTG -3’

Table M2. Primer sequences for FGFR4 exons 9-16
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Statistical Analysis
SPSS version 17 (IBM Corporation Somers, NY) was used to perform all statistical
test. Two-tailed Student’s t-test was used to test differences in sample means for data
with normally distributed means. Mann-Whitney U test was used alternatively for non
parametric data. Kaplan-Meier survival curves were generated and compared using a
2-sided log-rank statistic. The Cox proportional hazards model was used for
multivariate analysis. Pearson’s correlation coefficient was used to test linear
associations. A p value < 0.05 was considered statistically significant.
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Results
FGF1 and FGFR4 DNA copy number are significantly amplified in HGSC
Chromosome segment 5q31-35.3 was previously reported to be amplified and related
to poor prognosis by our group in high grade serous ovarian carcinoma [10]. A
correlation study between CGH and transcriptome profiling generated from 64
independent microdissected HGLS ovarian tumor samples identified 17 genes that
showed significant concurrence between DNA and mRNA copy numbers (Figure R1)
in addition to FGF1 that we previously described. FGFR4 located in the same
amplicon was found to show significant correlation between DNA and mRNA copy
number, further study using qRT-PCR analysis also showed significant positive
correlation between DNA copy number of FGF1 and FGFR4. (Figure R2).

Figure R1. qRT-PCR validation of genes present on segment 5q31-35.3 from 51 microdissected tumor
samples. Both FGF1 and the FGFR4 genes are significantly amplified and over-expressed in this area of the
chromosome, which is linked to poor survival in high grade serous ovarian cancer patients [10].
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Figure R2. DNA copy number of FGF1 and FGFR4 genes as determined by quantitative PCR from 51 micro
dissected tumor samples. Significant positive correlation is noted by person correlation (r=0.37, p<0.05,).

The FGFR4 protein is overexpressed in HGSC and is related to poor survival
Immunohistochemistry staining of FGFR4 in both normal ovarian surface epithelium
and fallopian tube demonstrated lower expression compared to stained tumor (figure
R3). FGFR4 expression score was found to correlate negatively with survival(r=-0.49
p<0.001, (Figure R4). The high FGFR4 Expression cohort demonstrated significantly
decreased survival in Kaplan-Meier survival analysis were median survival was 24
months compared with 55 months in the low expression cohort. Cox proportional
hazard model after stratifying for age and debulking status also demonstrated
increased risk of death with high FGFR4 expression (HR 2.1 p<0.01,Figure R5).

The FGFR4 and FGF1 proteins are over expressed in vitro in HGSC
Western blotting demonstrated a minimum 40 fold over expression of FGFR4 and
FGF1 proteins in HGSC cell line lysates compared to human surface epithelial cells
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Figure R3. Overexpression of FGFR4 in high grade serous ovarian carcinoma. Expression of FGFR4 in high
grade ovarian cancers (C1, C2) compared with ovarian surface epithelium (A) and fallopian tube epithelium (B) is
demonstrated with overexpression being noted.
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Figure R4. Correlation of FGFR4 expression score with patient survival. 183 HGSC tumor sections were
scored with a computer algorithm in arbitrary units for FGFR4 staining intensity (0=lowest – 255=highest). A
significant negative correlation is noted.
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Figure R5. FGFR4 overexpression is associated with poor survival in advanced stage high grade serous
ovarian carcinoma. (A) Kaplan-Meier survival function for 183 patients with HGSC divided into low and high
FGFR4 expression based on a median expression score cut-off. High FGFR4 expressors median survival was 24
months compared with 55 months in the low expression cohort. Correlation with survival is maintained after
stratification for age and debulking status. (B) Cox proportional hazard model indentified high FGFR4 expression as
an independent risk factor for death in HGSC.
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st in the OVCA432 cell line suggesting possible concurrent amplification of 5q 31-35.3. FGF1
A

β Actin

FGFR4

FGF1

A2780 SKOV3

Cell Line
OVCAR3 OVCA5 OVCA432 OVCA433 HOSE

B

Figure R6. Expression of FGFR4/FGF1 in high grade ovarian cell lines.(A) Western blots demonstrating
relative expression of FGF1/FGFR4 and β-actin in 6 HGSOC cell lines and human surface epithelial cells; (B)
Protein expression normalized to actin from the immunoblots shown in (A).

was not detectable in conditioned medium by ELISA (Figure R7) in any of the cs tested.
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Figure R7. FGF 1 in conditioned media from HGSC cell lines in vitro (A) Cells were plated on 100 mm plates
until 70% confluent, serum containing medium was removed and Opti-MEM media was added, incubation for 48
hours was then done, media collected, concentrated 50x and then subjected to FGF1 ELISA, none of the cells lines
demonstrated any measurable FGF1 production in the media.

(Figure R6). Both FGFR4 and FGF1 expression were highest in the OVCA432 cell line
suggesting possible concurrent amplification of 5q 31-35.3. FGF1 was not detectable
in conditioned medium (Figure R7) in any of the cell lines tested.

Exogenous FGF1 treatment increased proliferation and survival in HGSC and activated
multiple signaling pathways in vitro
Exogenous FGF1 significantly increased proliferation by 11-54% in 17 % of cell lines
tested, survival was also increased by a mean of 22% in 4 out 6 cell lines in vitro
(Figure R8 and R9-A). Treatment with exogenous FGF1 significantly increased
measured luminescence attributed to activation of the MAPK, WNT and NFkB
pathways by 41-53% in the Cignal Lenti OVCA432 reporter assay, no significant
change was noted in the remainder of the tested pathways (Figure R8). Activation of
the pathways was verified by western blotting (Figure R13). Reverse phase protein
array also indentified several proteins involved in cellular signaling that showed
increased phosphorylation in response to FGF1 treatment including MAPK, PI3K and
GSK3α. In addition, up regulation of BCL-xL and down regulation of E-cadherin was
35

shown (Figure R12 & Table R1). In vitro transfection of FGFR4 targeted siRNA was
successful in abrogating the effect of exogenous FGF1 in vitro both on cell behavior
and cell signaling (Figure.R9-B and R11) FGF1 did not increase cellular migration in
vitro in any cell line tested. Effects of selected FGF1 inhibitors and FGFR4 knock down
are shown in Figure R14. With the exception FGFR4 knockdown, none of the FGF1 or
FGFR inhibitors showed activity in vitro. However, FGFR4 trap protein was able to
block the effects of exogenous FGF1 on OVCA432.
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Figure R8. Effects of exogenous FGF1 on HGSC survival and proliferation in vitro. (A)Survival of HGSC cells
incubated in serum free media for 72 hours with different concentration of FGF1 as measured by WST 1. Several
cell lines demonstrate increased survival in a dose dependent fashion (B) Proliferation of HGSC cells, serum
starved for 24 hours, and incubated for 24 h afterwards with varying concentrations of FGF1 with 2% FBS( all data
points normalized to each cell lines control *=p<0.05, **=p<0.01, ***=p<0.001)
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Figure R9. Proliferation of OVCA432 under different concentrations of FGF with and without transient
FGFR4 knockdown (A) OVCA432 was plated in media containing 2% FBS for 24 hours on the XCELLigence array
to allow attachment, data where normalized to the 24 hr time point after which the media was supplemented with
FGF1 in different concentrations and the cells were followed for 84 hours using changes in electrical impendence to
generate a cell index reflecting the number of cells present. FGF1 was noted to cause increased proliferation in a
dose dependant manner(B) The experiment was then repeated with prior forward transient transfection with
scramble siRNA in the 24 period prior to addition of FGF1 at 10 ng/ml and 2% FBS to the medium, scramble siRNA
demonstrated significantly increased proliferation compared to the two FGFR4 Knockdown sequences

37

Figure R10. FGF1 effect on pathway activation in HGSC. Activation of signaling pathways in OVCA432 was
screened by treating HGSC cell lines expressing transcription response elements linked to a luciferase reporter
system with FGF1 and measuring subsequent light emission. MAPK , NFB and WNT pathway demonstrated
significant increases in activity (* = p<0.05 , **=p<0.01,***=p<0.001)

Figure R11. Transient FGFR4 knockdown reduced signaling activation triggered by FGF1. FGFR4 targeted
siRNAs successfully inhibited increased pathway activation measured by luminescence in the luciferase reporter
system previously described.
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Figure R12. Reversers phase protein array of OVCA432 treated at
several time points. The array used 209 antibodies to probed for
changes in expression levels of protein lysates After treatment with
FGF1.Activation of MAPK , PI3K and WNT pathway is noted. BCL-xL is
also up-regulated. E-Cadherin and cyclin B1 are down regulated.
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Up regulated Proteins

Fold change

Down regulated Proteins

Fold change

Phosphorylated MAPK(T202)

2.91

E. Cadherin

0.51

Bcl-xL

1.83

Cyclin B1

0.44

Phosphorylated GSK3α(S21)

1.54

Phosphorylated PI3K (110a)

1.51

Table R1. Up-regulated and down regulated proteins as shown by RPPA after treatment with FGF1 at 10 ng/ml for
3h

Aaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaaa

Figure R13. Pathway activation in OVCA432 treated with FGF1.Western blots demonstrating change in
phosphorylated protein levels in OVCA432 cells treated with FGF1 at 10 ng/ml for 1 hr (+) versus control (-).
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Figure R14. Effect of different inhibitors of the FGF pathway on HGSC in vitro(A)HGSC cell lines were plated
and serum starved for 24 hours and then media was removed with medium containing 2% FBS and one of 3 FGF
pathway inhibitors and difference in proliferation measured via WST-1 assay, no significant difference is
noted(B)HGSC cell lines were plated and serum starved for 24 hours and then media was removed with medium
containing 2% FBS and 10 ng/ml FGF1 and the FGFR4 pathway was either knocked down transiently or blocked
via FGFR4 trap protein, decrease in proliferation below normalization point is noted in the FGFR4 knock down arm
and FGFR4 trap successfully inhibited the effect of exogenous FGF1 on OVCA432 cell line *=p<0.05, **=p<0.01,
***=p<0.001)
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FGFR4 knock down in vitro decreases cell survival, proliferation and migration
Transfection with FGFR4 targeted siRNA resulted in significantly

decreased cell

survival (in serum reduced media) by 31-65% (Figure R15) and decreased
proliferation in media supplemented with 10% FBS by greater than 50% in all cell lines
tested (Figure R16) . Migration of several cell lines was also decreased significantly
from control (Figure R16).

Figure R15. Effects of transient FGFR4 siRNA knockdown on HGSC Survival in vitro. Survival of HGSC cell
lines after forward transfection with siRNA and incubation for 72 h in serum reduced media, significantly reduced
survival was noted in cells transfected with FGFR4 targeted siRNA compared to those with scramble siRNA as
measured by WST-1 assays,***=p<0.001.
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Figure R16. Effects of transient FGFR4 siRNA knockdown on HGSC proliferation in vitro. Proliferation of
HGSC cell lines after forward transfection with siRNA at multiple time points over 72 hr period, inhibition of
proliferation was demonstrated by both FGFR4 targeted siRNAs.
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Figure R17. Effects of transient FGFR4 siRNA knockdown on HGSC migration in vitro. (A) Migration/invasion
of HGSC cell lines into collagen matrix using ORIS assay system with and without the assay mask; (B)
Quantization of migration/invasion into the central zone of ORIS assay via measurement of green fluorescence
demonstrating a significant decrease in migration after FGFR4 knockdown(* = p<0.05 , **=p<0.01).
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FGFR4 kinase and inter-membrane domains from clinical samples do not contain
activating mutations
6 patients out of 43 (14%) were positive for the Gly388Arg polymorphism in the
intermembrane domain. Otherwise sequencing of exons 9 through 16 did not
demonstrate any mutations in either the kinase or intermembrane domain.

FGFR trap protein treatment reduced HGSC xenograft growth in vivo
The FGFR1 trap protein was able to significantly reduce growth of xenografts
OVCA432 in vivo as measured by serial luminescent imaging (Figure R18 & R19).
H&E staining of xenografts revealed increased tumor necrosis and reduced tumor
surrounding stroma (Figure 20)

Photon Emission

200000
150000
100000
50000
0
Week 0

Week 2

Control

Week 4

Week 6

FP1039

Figure R18. Quantitative Luminescent imaging of OVCA432 xenograft model treated with FP 1039. Two
groups of mice, each injected IP with 1x106 cells of OVCA432luc, then were imaged at baseline 1 week after
injection (week 0). Control group was injected 20 mg pooled human IgG twice weekly and FP 1039 group was
injected with the FGFR1 trap protein at the same dose and schedule. Significantly more luminescence is noted
from the control tumor group p<0.05
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Figure R 19. Tumor luminescence and distribution in OVCA432 treated with FP1039 versus control.
Inhibition of tumor growth is noted in the FP1039 group versus control.
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Figure 20. H&E sections from orthotopic xenograft tumors of OVCA432 in nude mice. (A) tumors from a
mouse treated with pooled human IgG (B) Tumor from a mouse treated with FP 1039 showing increased necrosis
(N)and minimal stroma compared to placebo group(S)
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Discussion and Conclusions
Advanced stage high-grade serous carcinoma, as with many solid tumors, has
undergone optimization of traditional therapeutic approaches over the last decade.
Although this has led to improvements in survival and initial response to therapy, most
patients with advanced stage disease still face poor prognosis, especially when in
relapse or with metastatic disease[6, 7]. Characterization of genetic aberrations in
these tumors and better understanding of molecular pathways involved in their
pathogenesis/progression has fueled the development of targeted biologic agents for
therapeutic intervention. When compared to traditional chemotherapy these agents
posses a greater therapeutic index secondary to their relative selectivity for neoplastic
cells[44]. In addition, biologic agents may have activity against those tumors that have
become resistant to cytotoxic drugs. The heterogeneity of solid tumor genetic
aberrations between patients has made it necessary to tailor such biologic therapy to
the suitable molecular targets present within a tumor[79]. Our work demonstrates a
possible target for such a personalized therapeutic approach in HGSC.
Our previous report demonstrated the negative impact on survival in HGSC tumors
harboring amplification of segment 5q31-35.3[10]. Although that segment contains
hundreds of genes, it is notable for presence of several members of the FGF family.
Evidence for the FGF pathway’s involvement in tumor development and progression is
substantial. Prior reports have demonstrated the role of the FGF family in driving cell
proliferation in solid tumors, including prostate and endometrial carcinomas[42, 80].
The proliferative effects appear to be mediated principally through the MAPK
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pathway[27]. Successful inhibition of FGF pathway mediated cancer growth with
biologic agents has been reported in vitro [54].
The mitogenic effects of FGF signaling may also be enhanced by activation of
antiapoptotic pathways through the PI3K pathway. In small cell lung cancer FGF2
overexpression is a known negative prognostic indicator. The decreased survival
associated with FGF2 appears to be mediated by a cytoprotective effect involving
upregulation of the expression of the antiapoptotic proteins Bcl2, Bcl-xL through S6
kinase[81].
FGF signaling can also promote cell migration. Pancreatic cancer cells in vitro, have
shown FGF10 and FGFR2 dependent invasion[82]. In a breast cancer mouse model
activation of FGFR1 kinase domain led to invasive mammary lesions. In that model
FGFR1 activation induced cell proliferation and survival, in addition to the gain of a
matrix metalloproteinase 3, resulting in an invasive phenotype[83].
Our results demonstrate that activation of the FGF signaling axis through FGFR4 in
HGSC leads to downstream activation of similar critical signaling pathways associated
with phenotypic changes characteristic of more aggressive carcinomas.
We have demonstrated the activation of MAPK pathway by FGF1/FGFR4 interaction
and resulting proliferative effect. Overexpression of the FGF1 ligand and the FGFR4
receptor in tumors with the 5q31-35.3 therefore may provide an autocrine signaling
loop that drives tumor growth and proliferation in HGSC. Through the same loop the
PI3K pathway may decrease apoptosis and increased survival of tumor cells.
Additional FGF ligand involvement is likely as knock down of FGFR4 in absence of
FGF1 and without known activating mutations leads to decreased cell proliferation and
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cell death. This may be due to autocrine FGF18 overexpression, as it is also located
on 5q311-35.3 amplicon, or other autocrine/paracrine FGF ligand production. It is also
evident that other pathways including WNT and NFkB are involved and their role is
currently under investigation by our group.
Our RPPA results also support that FGF1’s effect on cancer cells is mediated by
activation of several signaling pathways. It also suggests that FGF1 signaling may play
a more direct role in inhibiting apoptosis secondary to up regulation of Bcl-xL, and
migration/invasion as evidenced by downregulation of E-Cadherin. This is consistent
with previously published reports discussed earlier. However, the evidence we present
is preliminary and requires further investigation.
It also appears that different levels of FGFR4 amplification may have different effects
on cell response in HGSC. The response to exogenous FGF1 by OVCA432, the
highest expressor of FGFR4, demonstrated increased proliferation and survival but no
change in migratory behaviour Other cell lines with lower FGFR4 expression
demonstrated significant increases in migration/invasion in addition to survival but no
increase in proliferation.
We did not observe in vitro production of FGF1 in conditioned media, although it was
detected in cell lysate, and in tissue sections in our previous report [10]. This may be
due to a short half life for the protein. It may also be that release in vivo requires
certain conditions or co-signals that cannot be replicated by in monolayer cell culture
environment.
We have shown that in an orthotopic mouse model of HGSC use of the FP-1039
FGFR1 trap protein significantly decreases tumor growth. FP-1039 is a fusion protein
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of the extracellular domain of FGFR1 and IgG Fc fragment. The trap protein has broad
spectrum binding activity to FGF ligands including FGF1 and is currently in phase 2
trials in other gynecologic malignancies. The ability to sequester several FGF ligands
and to inhibit the pathway upstream of the receptor allows FP-1039 to inhibit all the
possible effects of overexpression of FGF ligands. This provides a therapeutic
approach that interrupts autocrine signaling loops, hypothetically decreasing
proliferation, survival and migration of tumor cells. Paracrine effects such as
angiogenesis may also be inhibited.
The challenge remains in identifying patients that may benefit from such an approach.
This may be possible through identifying genetic and epigenetic changes particularly in
genes involved in the FGF-FGFR axis that are associated with the responsiveness of
the FGFR trap in preclinical mouse models.
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